both beat it to market and Rinvoq also has head-to-head data showing improvement over Dupixent. The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs ...

The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns. Click to read why VRNA is a Hold.

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

Dupixent continues to be a significant growth ... targets a large market opportunity in thrombosis treatment. While the mechanism isn't fully de-risked and requires large, expensive Phase III ...

Monoclonal antibodies dupilumab (Dupixent), omalizumab (Xolair), and ... he predicted. How the drugs' mechanisms impact atopic disease is still being plumbed. "You have tezepelumab fail in atopic ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo ...